ACE2 and COVID-19: Agents that specifically disrupt lipid rafts and deplete rafts’ cholesterol have been proposed to reduce SARS-CoV-2 infectivity and COVID-19 severity because the SARS-CoV-2 host-cell-receptor angiotensin-converting enzyme 2 (ACE2) is localized into lipid rafts [91,92].